STOCK TITAN

Quest Diagnostics Inc. - $DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: $DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

Rhea-AI Summary
Quest Diagnostics (Ticker: DGX) recognized by Executive Women of New Jersey for Gender Diversity Initiatives
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics organized a summer internship program called Quest for Health Equity (Q4HE) in collaboration with the American Heart Association's (AHA) Historically Black Colleges and Universities (HBCU) and Hispanic Serving Institutions (HSI) programs. The program aimed to provide hands-on experience and professional development opportunities for scholars in STEM and healthcare. Participating interns had the chance to work with Quest professionals, access mentorship and networking opportunities, and contribute to a more diverse and inclusive workforce. The press release highlights the experiences and achievements of three interns from different universities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics highlights in their 2022 Corporate Responsibility Report include over 1 million hours of employee training, $3.3 million in tuition reimbursement, and a 75 employee engagement survey score surpassing the industry average.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
Rhea-AI Summary
Quest Diagnostics announces pricing of $750 million senior notes due 2033 in a public offering. The net proceeds will be used for general corporate purposes, including the redemption or repayment of indebtedness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
-
Rhea-AI Summary
Diadem forms strategic collaboration with Quest Diagnostics to develop and market a blood-based test for Alzheimer's disease. The test has Breakthrough Device Designation and can identify a variant of the p53 protein implicated in AD. The collaboration aims to improve access to high-quality blood tests for evaluating AD risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics focuses on enhancing employee experience, cultivating an inclusive workforce, enabling development, and retaining talent. They implemented training modules to foster inclusion and diversity. Key highlights include 59.7% of management identifying as female and 36.4% identifying as people of color.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Quest Diagnostics reports Q3 2023 financial results with a 7.7% decrease in revenues and a 9.7% decrease in diluted EPS compared to 2022. Base business revenues increased by 4.6%. Full year 2023 revenue guidance is between $9.19 billion and $9.24 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
-
Rhea-AI Summary
Quest Diagnostics supports Women's Breast & Heart Initiative's National Pink Day wellness event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics expands healthcare access and affordability
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
Rhea-AI Summary
Neway forms lab services agreement with Quest Diagnostics to speed quality ESRD testing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Quest Diagnostics Inc.

NYSE:DGX

DGX Rankings

DGX Stock Data

15.21B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
SECAUCUS

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator